Accenture: Large-scale agency M&A is 'not our game' as we have 'amazing momentum'

Accenture: Large-scale agency M&A is 'not our game' as we have 'amazing momentum'

Accenture will not consider a takeover bid for a large ad agency group because its chief executive says there has been a "100%" failure rate with such deals.

WPP names Karen Blackett as its first UK country manager

WPP names Karen Blackett as its first UK country manager

WPP has named Karen Blackett as its first UK country manager, making her the most important agency leader in the British ad industry.

Five things for pharma marketers to know: Monday, January 8, 2018

Five things for pharma marketers to know: Monday, January 8, 2018

Celgene to buy Impact Biomedicines for up to $7 billion; Pfizer plans to cut 300 positions in neuroscience; Perrigo hires new CEO

How healthbots can assist patients and HCPs

How healthbots can assist patients and HCPs

As HCPs continue to be stretched for time to diagnose and interact with patients, health bots could help reduce HCP workload and drive patient engagement.

The buyer's guide to pharma, healthcare, and life sciences consultancies

The buyer's guide to pharma, healthcare, and life sciences consultancies

Do the healthcare and pharma arms of Accenture, Deloitte, PwC, and other consultancies pose an existential threat to traditional healthcare agencies?

Five things for pharma marketers to know: Friday, January 5, 2018

Five things for pharma marketers to know: Friday, January 5, 2018

Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise

From working for one administration to fending off another: Planned Parenthood's Kevin Griffis

From working for one administration to fending off another: Planned Parenthood's Kevin Griffis

Kevin Griffis brought his experience in government and politics to Planned Parenthood at the perfect time, leading the fight to protect birth control coverage under the Trump administration and destigmatizing abortion.

Bank brand creates own algorithm to avoid YouTube ad pitfalls

Bank brand creates own algorithm to avoid YouTube ad pitfalls

US bank JPMorgan Chase has returned to advertising on YouTube only after developing its own algorithm that ensures its ads are not placed around questionable content.

Five things for pharma marketers to know: Thursday, January 4, 2018

Five things for pharma marketers to know: Thursday, January 4, 2018

Allergan to cut 1,000 jobs; McKesson acquires RxCrossroads from CVS Health; Pfizer and Sangamo enter collaboration to develop ALS gene therapy

Five things for pharma marketers to know: Wednesday, January 3, 2018

Five things for pharma marketers to know: Wednesday, January 3, 2018

Utah Senator who backed Orphan Drug Act will not seek reelection; medicines more expensive in 2018; Spark's genetic therapy for rare blindness costs $850,000

Should pharma fear ICER?

Should pharma fear ICER?

The group's reports, received with great interest by insurers and the Department of Veteran Affairs, have concluded certain high-profile drugs aren't worth the cost. Pharma still hasn't decided whether ICER is friend or foe.

CPG companies Nestlé and Kellogg court OTC

CPG companies Nestlé and Kellogg court OTC

A sea change may be afoot in OTC, with multiple healthcare businesses in play. Could consumer goods companies fill the void left by big pharma?

Five things for pharma marketers to know: Tuesday, January 2, 2018

Five things for pharma marketers to know: Tuesday, January 2, 2018

FDA approvals hit a 21-year high; drug prices account for higher U.S. healthcare spend; industry enters 2018 amidst consolidation, uncertainty

Five things for pharma marketers to know: Thursday, December 28, 2017

Five things for pharma marketers to know: Thursday, December 28, 2017

Study: male docs earn more than female peers; new Michigan law tackles opioid crisis; study: some docs billed Medicare for most expensive patient visit type

MM&M's 5 most-read technology stories of 2017

MM&M's 5 most-read technology stories of 2017

Digital innovation in Japan, health-tech trends, and social media top the list.

VA reaches out to agencies about recruitment campaign

VA reaches out to agencies about recruitment campaign

The Department of Veteran Affairs issued an RFI at the end of November for a nationwide healthcare professional recruitment campaign.

Five things for pharma marketers to know: Wednesday, December 27, 2017

Five things for pharma marketers to know: Wednesday, December 27, 2017

Mallinckrodt to buy Sucampo for $1.2 billion; Amazon pushes digital advertising in 2018; WHO classifies gaming disorder as mental health condition

MM&M's 5 most-read agency stories of 2017

MM&M's 5 most-read agency stories of 2017

The agency issue, people moves, and a series of restructures top the list.

Merck comms head Adele Ambrose to retire

Merck comms head Adele Ambrose to retire

VP of investor relations Teri Loxam will take over Ambrose's role in January.

Five things for pharma marketers to know: Tuesday, December 26, 2017

Five things for pharma marketers to know: Tuesday, December 26, 2017

Roche to buy Ignyta for $1.7 billion; FDA OKs Valeant eye drop for OTC sale; Kmart settles prescription drug fraud allegations

MM&M'S most-read stories of 2017

MM&M'S most-read stories of 2017

Topping the list: The MM&M agency issue, the MM&M Awards winners and shortlist, and how a porn star is providing sex ed to seniors

Five things for pharma marketers to know: Thursday, December 21, 2017

Five things for pharma marketers to know: Thursday, December 21, 2017

BI to pay $13.5 million for misleading marketing; ICER: CAR-T therapies more cost-effective than chemotherapy; FDA approves Roche's breast cancer combo therapy

Cancer Research UK 'Right Now' campaign returns to highlight research impact

Cancer Research UK 'Right Now' campaign returns to highlight research impact

Cancer Research UK's 'Right Now' brand campaign will return in 2018 with a new focus highlighting the impact that research has on people suffering with cancer.

Kaiser Permanente hires Kathy Beiser as chief comms officer

Kaiser Permanente hires Kathy Beiser as chief comms officer

Beiser previously held leadership roles at Edelman, Hilton, Discover, and Burson-Marsteller.

Five things for pharma marketers to know: Wednesday, December 20, 2017

Five things for pharma marketers to know: Wednesday, December 20, 2017

Tax bill could lead pharma to move overseas; global pharma sales increased 45% in nine years; FDA OKs first gene therapy for rare retinal disease

Twitter to brands: 280 characters may not be for you

Twitter to brands: 280 characters may not be for you

Brands should refrain from tweets that are over 100 characters, according to Twitter's director of brand strategy.

FDA campaign reframes quitting for smokers

FDA campaign reframes quitting for smokers

The Every Try Counts campaign to change how smokers see their last attempt to quit.

Five things for pharma marketers to know: Tuesday, December 19, 2017

Five things for pharma marketers to know: Tuesday, December 19, 2017

Pharma industry spent $57 million on lobbying in 2016; Humana, private equity firms to buy Kindred for $4 billion; price of old glaucoma drug skyrockets

Five things for pharma marketers to know: Monday, December 18, 2017

Five things for pharma marketers to know: Monday, December 18, 2017

CVS/Aetna deal will affect healthcare benefits; lawmakers pressure DEA to curb painkiller supply; Allergan and Richter's Vraylar sees positive results for bipolar depression

Janssen makes cancer info easy to find on the web

Janssen makes cancer info easy to find on the web

The pharma unit of Johnson & Johnson launched the Cancer.com website this month.

Five things for pharma marketers to know: Thursday, December 14, 2017

Five things for pharma marketers to know: Thursday, December 14, 2017

Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer's biosimilar to J&J's Remicade; Novartis to downsize generics business

Five things for pharma marketers to know: Friday, December 15, 2017

Five things for pharma marketers to know: Friday, December 15, 2017

FDA approves first topical skin growth treatment; Teva to cut 14,000 jobs; Novartis Oncology CEO resigns

Mitsubishi Tanabe's Kevin O'Brien on driving unmet needs

Mitsubishi Tanabe's Kevin O'Brien on driving unmet needs

The VP of market access at Mitsubishi Tanabe Pharma America discusses driving access and bringing to market the first FDA-approved ALS drug in years.

Five things for pharma marketers to know: Wednesday, December 13, 2017

Five things for pharma marketers to know: Wednesday, December 13, 2017

Teva diminishes debt with job cuts and sale; FDA to study whether consumers can detect misleading ads; AbbVie, Roche present positive Phase-III data at ASH

Ironwood strengthens leadership with two new hires

Ironwood strengthens leadership with two new hires

The drugmaker named William Huyett as COO and Gina Consylman as SVP and CFO.

Rejuvenan Global Health names Hudson Cutler communications AOR

Rejuvenan Global Health names Hudson Cutler communications AOR

The digital health startup was founded in 2015.

Five things for pharma marketers to know: Tuesday, December 12, 2017

Five things for pharma marketers to know: Tuesday, December 12, 2017

FDA issues prescription drug promotion guidance; FDA approves first follow-on biologic of Lilly's Humalog; drugmakers allegedly hired nurses to promote drugs

Amarin's Salyer preps for Vascepa push

Amarin's Salyer preps for Vascepa push

Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has "a great story to tell, with or without the data."

GCI Health confirms Jones and Kerry as joint MDs of London operation

GCI Health confirms Jones and Kerry as joint MDs of London operation

GCI Health has confirmed new hire Kath Kerry and maternity leave returner Rikki Jones as co-MDs of its London operation, the network's second hub alongside its New York headquarters.

Five things for pharma marketers to know: Monday, December 11, 2017

Five things for pharma marketers to know: Monday, December 11, 2017

Pfizer's Viagra generic to sell for half the price; GSK seeks oncology deals; Ionis' experimental Huntington's drug tackles toxic protein for the first time

Infographic | HCPs must deal with communication breakdown

Infographic | HCPs must deal with communication breakdown

Drugmakers are proud of the patient service programs they've developed. Yet there remains a disconnect in the way information is communicated to HCPs.

TAG-certified channels have 83% fewer incidences of ad fraud

TAG-certified channels have 83% fewer incidences of ad fraud

A study has found that channels certified by the Trustworth Accountability Group (TAG) had 83% less ad fraud than the broader industry average.

Terry Savage to leave Cannes Lions after 33 years

Terry Savage to leave Cannes Lions after 33 years

Cannes Lions' longtime leader, chief spokesman, and a figure many viewed as the heart and soul of the global creativity festival will be moving on after the 2018 event ends.

Five things for pharma marketers to know: Friday, December 8, 2017

Five things for pharma marketers to know: Friday, December 8, 2017

FDA approves first nebulized LAMA COPD treatment; more than 2,000 cancer immunotherapies in development; FDA issues 3D-printing guidance

Five things for pharma marketers to know: Thursday, December 7, 2017

Five things for pharma marketers to know: Thursday, December 7, 2017

UnitedHealth Group to buy DaVita primary care unit for $4.9 billion; Roche drug combo doubles lung-cancer survival in trial; study: FDA programs expedite drug approval

GCI Health puts Edie DeVine in charge of medical, health tech

GCI Health puts Edie DeVine in charge of medical, health tech

DeVine will oversee the agency's health IT and medical device work.

Lighthouse wins grand prize for voice-activated diabetes app at Hitlab

Lighthouse wins grand prize for voice-activated diabetes app at Hitlab

Lighthouse received $50,000 for application aimed at providing more accessible and engaging care for those living with diabetes.

What happens as marketers shift from algorithms to AI and other 2018 predictions

What happens as marketers shift from algorithms to AI and other 2018 predictions

Next year will be the start of the shift from marketing algorithms to AI, predicts Kantar Millward Brown.

Five things for pharma marketers to know: Wednesday, December 6, 2017

Five things for pharma marketers to know: Wednesday, December 6, 2017

FDA approves Novo's diabetes drug; Walgreens undergoes rebranding in the wake of CVS-Aetna merger; pharma increasingly transparent about clinical trial data

Experts weigh in: How will health technology advance in 2018?

Experts weigh in: How will health technology advance in 2018?

Innovation-minded executives share their thoughts and predictions for the year ahead.

How will the pharma industry fare in 2018 under Trump?

How will the pharma industry fare in 2018 under Trump?

The first year of the Trump administration was kind to pharma, but it might not be so fortunate in 2018.

Five things for pharma marketers to know: Tuesday, December 5, 2017

Five things for pharma marketers to know: Tuesday, December 5, 2017

Botox-like wrinkle-reducer shows positive results in trials; investors double down on fertility; few websites transparent about pricing, study finds

GroupM unveils upbeat global adspend forecast for 2018

GroupM unveils upbeat global adspend forecast for 2018

GroupM, the media investment arm of WPP, forecasts global ad growth of 4.3% in 2018, and predicts Google and Facebook will strengthen their stranglehold on digital advertising.

'Coco' filmmakers discover family history in latest Ancestry spot

'Coco' filmmakers discover family history in latest Ancestry spot

Content Collective takes the Pixar film's creators on their own genealogy journeys.

Five things for pharma marketers to know: Monday, December 4, 2017

Five things for pharma marketers to know: Monday, December 4, 2017

CVS to buy Aetna for $69 billion; J&J buys commercial rights for biotech's experimental hypertension drug; Republicans repeal Obamacare's individual mandate

The 2018 pipeline report: Aspiring assets to keep an eye on

The 2018 pipeline report: Aspiring assets to keep an eye on

The most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch.

Publicis.Sapient's Alan Wexler steps up as digital chief Chip Register retires

Publicis.Sapient's Alan Wexler steps up as digital chief Chip Register retires

Publicis Groupe has named Alan Wexler as chief executive of Publicis.Sapient as Chip Register has chosen to retire at the end of the year.

Five things for pharma marketers to know: Thursday, November 30, 2017

Five things for pharma marketers to know: Thursday, November 30, 2017

FDA releases information on Exondys 51; Sanofi's dengue vaccine faces new restrictions; Kellyanne Conway named opioid czar

HHS nominee Alex Azar: Medicare Part B should negotiate drug prices

HHS nominee Alex Azar: Medicare Part B should negotiate drug prices

Alex Azar, previously a senior executive at Eli Lilly, proposed granting Part B the authority to negotiate lower prices.

Five things for pharma marketers to know: Wednesday, November 29, 2017

Five things for pharma marketers to know: Wednesday, November 29, 2017

U.K. to be first to sell OTC Viagra; Regeneron offers startup scientific expertise; docs more likely to get poor marks when they reject patient requests

Amazon sets its sights on healthcare

Amazon sets its sights on healthcare

How worried should the industry's other major players be?

Pfizer campaign aims to keep boomers healthy

Pfizer campaign aims to keep boomers healthy

Company enlists Patti LaBelle to increase awareness for the pneumococcal pneumonia vaccine

Five things for pharma marketers to know: Tuesday, November 28, 2017

Five things for pharma marketers to know: Tuesday, November 28, 2017

FDA plans new guidance to bring complex generics to market more quickly; BioMarin sells priority review voucher for $125 million; Takeda expects Zika clinical trial results next year

OPDP issues third enforcement letter of 2017

OPDP issues third enforcement letter of 2017

The FDA's Office of Prescription Drug Promotion issued a warning letter to Amherst Pharmaceuticals and Magna Pharmaceutical.

Facebook explains advertising policies to its users but industry wants more

Facebook explains advertising policies to its users but industry wants more

Facebook has formally outlined is advertising policies to its users but the industry feels the internet giant is offloading responsibility instead of stepping up.

Five things for pharma marketers to know: Monday, November 27, 2017

Five things for pharma marketers to know: Monday, November 27, 2017

Teva to cut thousands of U.S. jobs; Regeneron drops Eylea combo drug development; insurers, drugstores, and hospitals increasingly teaming up

How working with Apple inspired Jeff Tangney to found Doximity

How working with Apple inspired Jeff Tangney to found Doximity

The CEO's experience launching medical reference app Epocrates led him to found a social network for physicians.

Five things for pharma marketers to know: Wednesday, November 22, 2017

Five things for pharma marketers to know: Wednesday, November 22, 2017

WebMD reportedly lays off 10% of workforce; Roche blocks Herceptin biosimilar with patent suit; insurers cover Collegium's Xtampza over Purdue's OxyContin

Five things for pharma marketers to know: Tuesday, November 21, 2017

Five things for pharma marketers to know: Tuesday, November 21, 2017

J&J to hold meeting on maintaining Remicade market share; Acorda ends development of Parkinson's drug; Darzalex notches positive first-line results

PRWeek and MM&M hire NBC exec for custom content role

PRWeek and MM&M hire NBC exec for custom content role

Emmy-nominated Maia Samuel becomes executive director of expanded Haymarket Content Lab; Bernadette Casey promoted to executive director of Haymarket Content Hub.

What does Twitter's 280 characters mean for pharma?

What does Twitter's 280 characters mean for pharma?

Marketers survey the pluses and minuses of the platform's new 280-character limit.

Five things for pharma marketers to know: Monday, November 20, 2017

Five things for pharma marketers to know: Monday, November 20, 2017

The FDA approves EpiPen competitor Auvi-Q for small children; pharma executives are warm up to Amazon; Purdue approached states about opioid-epidemic settlement

Five things for pharma marketers to know: Friday, November 17, 2017

Five things for pharma marketers to know: Friday, November 17, 2017

FDA approves Genentech's hemophilia drug; former Insys CEO pleads not guilty to bribery charges; federal jury rules in favor of Endo in Testim lawsuit

Five things for pharma marketers to know: Thursday, November 16, 2017

Five things for pharma marketers to know: Thursday, November 16, 2017

Docs biased against research from poor countries, study finds; Astellas probed over patient-assistance charity support; Acorda reports deaths in Parkinson's trial

Lions Health to remain segregated after Cannes revamp

Lions Health to remain segregated after Cannes revamp

Lions Health still stands as a separate two-day event, despite a sweeping revamp of the Cannes Lions festival, disappointing some who decried its lack of full integration within the larger program.

Cut-down Cannes 'saluted' by Publicis despite pull-out, as others give more cautious welcome

Cut-down Cannes 'saluted' by Publicis despite pull-out, as others give more cautious welcome

French holding company Publicis has welcomed the raft of changes announced to the Cannes Lions festival Monday, while others have given it a more cautious welcome.

Five things for pharma marketers to know: Wednesday, November 15, 2017

Five things for pharma marketers to know: Wednesday, November 15, 2017

FDA approves AstraZeneca asthma drug; Senate tax reform bill would repeal Obamacare mandate; J&J drops Remicade biosimilar lawsuit

Centers for Medicare and Medicaid Services puts $900m IDIQ up for bid

Centers for Medicare and Medicaid Services puts $900m IDIQ up for bid

Ketchum, Ogilvy, Porter Novelli, Weber Shandwick, and FleishmanHillard are among the firms that have been awarded past Centers for Medicare and Medicaid Services IDIQ accounts.

Drugmakers and celebrities partner to raise diabetes awareness

Drugmakers and celebrities partner to raise diabetes awareness

Celebrities such as Angela Bassett and Mike Golic share their personal experiences about diabetes.

Five things for pharma marketers to know: Tuesday, November 14, 2017

Five things for pharma marketers to know: Tuesday, November 14, 2017

FDA approves first digital pill; biotech companies race to develop cancer-fighting microbiome drugs; Loxo and Bayer reach $1.55 billion deal for rare cancer drugs

Five things for pharma marketers to know: Monday, November 13, 2017

Five things for pharma marketers to know: Monday, November 13, 2017

Dynavax receives FDA approval for hepatitis-B vaccine; Novartis strikes R&D deal with gene-editing startup; White House nominates new HHS head

Edelman health veteran Donna Duncan joins W2O Chicago

Edelman health veteran Donna Duncan joins W2O Chicago

W2O's Windy City office has added three health and analytics leaders over the past six months.

Former HealthCare.gov comms staffers fill in for the government with ACA campaign

Former HealthCare.gov comms staffers fill in for the government with ACA campaign

Get America Covered is working to encourage consumers to sign up for coverage through the Affordable Care Act.

Five things for pharma marketers to know: Friday, November 10, 2017

Five things for pharma marketers to know: Friday, November 10, 2017

AstraZeneca sales fall on generic competition; Anthem broadens access for Duchenne muscular dystrophy drug; researchers are developing new biopsy techniques

Five things for pharma marketers to know: Thursday, November 9, 2017

Five things for pharma marketers to know: Thursday, November 9, 2017

GSK hires Google biotech exec to lead R&D; Merck gets FDA-approval for CMV therapy; ex-Lilly exec reportedly top HHS secretary pick

Omnicom promotes Biolumina and H&S presidents to CEO

Omnicom promotes Biolumina and H&S presidents to CEO

Ty Curran, previously CEO of the sister agencies, will serve as chairman in 2018.

Armed with predictive analytics, PBMs push adherence as a stand-in for outcomes

Armed with predictive analytics, PBMs push adherence as a stand-in for outcomes

Pharmacy benefit managers are increasingly measuring a patient's outcome in the context of adherence.

Five things for pharma marketers to know: Wednesday, November 8, 2017

Five things for pharma marketers to know: Wednesday, November 8, 2017

FDA to change Risk Evaluation Mitigation Strategies to prevent delayed generic approvals; Ohio rejects drug-price measure; Aetna CEO wants to improve in-person pharmacy experience

Limits on pharma payments to doctors back on policy menu

Limits on pharma payments to doctors back on policy menu

A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.

Five things for pharma marketers to know: Tuesday, November 7, 2017

Five things for pharma marketers to know: Tuesday, November 7, 2017

Senator investigates Alkermes' opioid-marketing tactics; FDA approves Roche cancer drugs; CVS to launch next-day delivery nationwide

CDC tells opioid addiction stories with message: 'It only takes a little to lose a lot'

CDC tells opioid addiction stories with message: 'It only takes a little to lose a lot'

The CDC has launched the first wave of its awareness campaign about prescription opioids.

Maurice Lévy on his 30 years in charge of Publicis Groupe

Maurice Lévy on his 30 years in charge of Publicis Groupe

Midway through Campaign's audience with Publicis Groupe's Maurice Lévy, a heavily French-accented voice exclaims, "Now it is time for the real boss to arrive."

Five things for pharma marketers to know: Monday, November 6, 2017

Five things for pharma marketers to know: Monday, November 6, 2017

Valeant sells Addyi back to Sprout; some advertisers halt business with Outcome Health; Amgen cuts R&D jobs

P&G slashed the number of sites it ran ads on by nearly 70% after YouTube brand safety scandal

P&G slashed the number of sites it ran ads on by nearly 70% after YouTube brand safety scandal

In April, a month or so after brands were accused of funding terrorist videos on YouTube, Procter & Gamble cut down the number of sites its ads ran on by 69%.

Barby Ingle on the challenges of healthcare influencer marketing

Barby Ingle on the challenges of healthcare influencer marketing

The blogger talks the challenges of influencer marketing in healthcare, chronic disease, and big brand activations.

Five things for pharma marketers to know: Friday, November 3, 2017

Five things for pharma marketers to know: Friday, November 3, 2017

Experimental Gilead and GSK HIV drugs are expected to compete; GSK R&D head resigns; Valeant subsidiary scores eye-drug approval

Five things for pharma marketers to know: Thursday, November 2, 2017

Five things for pharma marketers to know: Thursday, November 2, 2017

Teva reports lower-than-expected Q3 earnings; BI and Dicerna partner in NASH drug development; AstraZeneca's experimental asthma drug fails in Phase-III

Pfizer bolsters Eucrisa launch with two DTC campaigns

Pfizer bolsters Eucrisa launch with two DTC campaigns

Forecasts anticipate sales of $1.3 billion in five years.

Front seat to the comms evolution: Abbott's Melissa Brotz

Front seat to the comms evolution: Abbott's Melissa Brotz

The divisional VP and head of public affairs has seen it all, including the transformation from a traditional comms organization to a more dynamic and content-led group.

Analysts agree with WPP that threat from consultancies has been 'overhyped'

Analysts agree with WPP that threat from consultancies has been 'overhyped'

During its third quarter earnings call yesterday, WPP dismissed the threat from management consultants as "overhyped". Analysts concur.